Evidence map›Paper›PMID 37398357›Full record

ArticlebioRxiv : the preprint server for biology2023

Single-tier point-of-care serodiagnosis of Lyme disease.

Rajesh Ghosh, Hyou-Arm Joung, Artem Goncharov, Barath Palanisamy, Kevin Ngo, Katarina Pejcinovic, Nicole Krockenberger, Elizabeth J Horn, Omai B Garner, Ezdehar Ghazal and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Rajesh GhoshBioengineering Department, University of California, Los Angeles, CA 90095 USA.
Hyou-Arm JoungElectrical & Computer Engineering Department, University of California, Los Angeles, CA 90095 USA.
Artem GoncharovElectrical & Computer Engineering Department, University of California, Los Angeles, CA 90095 USA.
Barath PalanisamyBioengineering Department, University of California, Los Angeles, CA 90095 USA.
Kevin NgoBioengineering Department, University of California, Los Angeles, CA 90095 USA.
Katarina PejcinovicBioengineering Department, University of California, Los Angeles, CA 90095 USA.
Nicole KrockenbergerBioengineering Department, University of California, Los Angeles, CA 90095 USA.
Elizabeth J HornLyme Disease Biobank, Portland, Oregon 97221, United States.
Omai B GarnerDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095 USA.
Ezdehar GhazalDepartment of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, New York 10595, United States.
Andrew O'KulaDepartment of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, New York 10595, United States.
Paul M ArnaboldiDepartment of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, New York 10595, United States.
Raymond J DattwylerDepartment of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, New York 10595, United States.
Aydogan OzcanBioengineering Department, University of California, Los Angeles, CA 90095 USA.
Dino Di CarloBioengineering Department, University of California, Los Angeles, CA 90095 USA.
University of California, Los Angeles · USCalifornia NanoSystems Institute · USNew York Medical College · US

Funding

A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme diseaseR44AI150060 · NIAID · BIOPEPTIDES, INC. · PI ARNABOLDI, PAUL MICHAEL, DI CARLO, DINO · 2020 to 2023
$3.3M
NIAID NIH HHS R44 AI150060
6 · The paper itself

Abstract

Point-of-care (POC) serological testing provides actionable information for several difficult to diagnose illnesses, empowering distributed health systems. Accessible and adaptable diagnostic platforms that can assay the repertoire of antibodies formed against pathogens are essential to drive early detection and improve patient outcomes. Here, we report a POC serologic test for Lyme disease (LD), leveraging synthetic peptides tuned to be highly specific to the LD antibody repertoire across patients and compatible with a paper-based platform for rapid, reliable, and cost-effective diagnosis. A subset of antigenic epitopes conserved across

Identifiers

PMID37398357
PMCPMC10312703
OpenAlexW4380606548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.